You searched for "AI"
APAM (Association of Physicians of Great Britain and Ireland) 118th Annual Meeting 2025
Welcome to APAM 2025 - What Awaits? APAM 2025, the 118th Annual Meeting of the AoPGBI, will take place on 3–4 April 2025 at the Royal College of Physicians in London. This prestigious event will bring together leading clinicians, researchers,...Announcing a new specialist distributor of medical devices for prostate cancer
Healthcare Supply Solutions are a new distributor focussed on medical devices for the diagnosis and management of Prostate Cancer.Innovations in flexible ureteroscopy for renal calculi: a comprehensive review
This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Flexible ureteroscopy (f-URS) has become a core modality in the treatment of...Shared decision-making – minimising the mismatch
In Western countries, we are spoilt for choice in almost every aspect of our lives, but does that reflect also in healthcare? While we have taken some big strides towards shared decision-making with our patients, the age-old physician dominance remains...Prostate Scotland appoints digital technology leader Peter Proud as new trustee
Prostate Scotland has appointed Peter Proud, Founder and CEO of Edinburgh-based digital technology company Forrit, to its Board of Trustees. Bringing more than 30 years of experience in digital transformation, data, and AI-driven innovation, Peter will support the charity’s work...
The case against omitting systematic biopsy in younger men
In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...
Preoperative risk stratification of high-risk prostate cancer patients
High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...
